This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.
Nandana V A,
Abstract
Chandanasava, a traditional Ayurvedic formulation, is recognized for its potential alkalizing properties, which may help restore acid-base homeostasis in conditions such as renal tubular acidosis (RTA). This study aims to investigate the active components of Chandanasava and their interactions with key renal target proteins, Pendrin and Carbonic Anhydrase II, which are essential for maintaining acid-base balance. An in silico approach was utilized to explore the pharmacological potential of the phytochemicals present in Chandanasava as therapeutic agents for RTA. We got the protein structures from the RCSB Protein Data Bank and the ligands from the IMPPAT database. ADME (Absorption, Distribution, Metabolism, and Excretion) analysis was performed using SwissADME to evaluate the pharmacokinetic properties of the ligands. Protein purification was conducted using Biovia Discovery Studio, where non-structural atoms were removed and validated using the Ramachandran plot. Molecular docking studies were performed using PyRx to assess the binding affinities between the phytochemicals and the target proteins. Post-docking analysis was carried out in Biovia Discovery Studio to obtain 3D and 2D structures and to evaluate non-bonded interactions between the amino acids. A total of 67 active components from Chandanasava were identified and analyzed for their binding interactions with Pendrin and Carbonic Anhydrase II. The results revealed that several ligands exhibited strong binding affinities to the target proteins, with binding scores ranging from -9.3 to -9.5 kcal/mol considered significant for further investigation. Notably, Proximadiol and 3,6-Bis(benzo[d][1,3]dioxol-5-yl)tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diol demonstrated the highest binding affinities for Carbonic Anhydrase II and Pendrin respectively, indicating their potential as targeted therapies for restoring acid-base homeostasis in RTA. The findings of this study suggest that the active components of Chandanasava may represent promising candidates for the development of new therapeutic strategies for renal tubular acidosis. This research provides a foundation for future experimental studies to validate the efficacy of these phytochemicals in clinical applications.
Keywords: Chandanasava, renal tubular acidosis, Pendrin, Carbonic Anhydrase II, molecular docking, phytochemicals, acid-base homeostasis
[This article belongs to International Journal of Bioinformatics and Computational Biology ]
Nandana V A. Investigating The Alkalizing Potential of Chandanasava For Restoring Acid-Base Homeostasis in Renal Tubular Acidosis: A Computational and In Silico Pharmacological Study. International Journal of Bioinformatics and Computational Biology. 2025; 03(02):-.
Nandana V A. Investigating The Alkalizing Potential of Chandanasava For Restoring Acid-Base Homeostasis in Renal Tubular Acidosis: A Computational and In Silico Pharmacological Study. International Journal of Bioinformatics and Computational Biology. 2025; 03(02):-. Available from: https://journals.stmjournals.com/ijbcb/article=2025/view=216479
References
1. Soriano JR. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160–70.
2. Rodríguez-Soriano J, Vallo A, Tapia C, Castillo G. Renal tubular acidosis. Pediatr Nephrol. 1990;4:268–75.
3. Alexander RT, Kurman JS, Jacinto J. Renal tubular acidosis. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Springer; 2016. p. 973–91.
4. Laing CM, Unwin R. Renal tubular acidosis. J Nephrol. 2006;19(Suppl 9):S46–52.
5. Palmer BF, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021;38:949–68.
6. Gil-Peña H, Mejia N, Santos F. Renal tubular acidosis. J Pediatr. 2014;164(4):691–8.
7. Bagga A, Bajpai A, Hari P. Renal tubular acidosis. Indian J Pediatr. 2020;87(9):733–44.
8. Laing CM, Karet FE. Renal tubular acidosis: developments in our understanding of the molecular basis. Int J Biochem Cell Biol. 2005;37(6):1151–61.
9. Vinothkanna A, Krishnan V, Pugazhendhi A, Arulvasu C, Karunakaran K, Kumar SS, et al. GC–MS and network pharmacology analysis of the ayurvedic fermented medicine, Chandanasava, against chronic kidney and cardiovascular diseases. Appl Biochem Biotechnol. 2023;195(5):2803–28.
10. Vinothkanna A, Krishnan V, Balamurugan K, Arulvasu C. Influence of intrinsic microbes on phytochemical changes and antioxidant activity of the Ayurvedic fermented medicines: Balarishta and Chandanasava. AYU. 2018;39(3):169–81.
11. Vinothkanna A, Arulvasu C, Krishnan V. Assessment of anti-arthritic potential of traditionally fermented ayurvedic polyherbal product Chandanasava by molecular modelling, docking and dynamics approaches. Int J Comput Biol Drug Des. 2018;11(4):346–68.
12. Shripathi R, Usha YN, Hugar DS. Clinical indications of Chandanasava: an experiential and scientific view. Int Res J Ayurveda Yoga. 2021;4(2):93–6.
13. Soleimani M. The multiple roles of pendrin in the kidney. Nephrol Dial Transplant. 2015;30(8):1257–66.
14. Wall SM, Pech V, Mount DB. The role of pendrin in renal physiology. Annu Rev Physiol. 2015;77:363–78.
15. Scialla JJ. The balance of the evidence on acid-base homeostasis and progression of chronic kidney disease. Kidney Int. 2015;88(1):9–11.
16. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol. 2009;20(2):251–4.
17. Mannon RB, Tushar V, Li Q. Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection? Am J Physiol Renal Physiol. 2020;319(6):F1090–104.
18. Rodríguez-Soriano J. New insights into the pathogenesis of renal tubular acidosis–from functional to molecular studies. Pediatr Nephrol. 2000;14:1121–36.
19. Soleimani M. The multiple roles of pendrin in the kidney. Nephrol Dial Transplant. 2015;30(8):1257–66.
20. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983;80(9):2752–6.
21. Purkerson JM, Schwartz GJ. The role of carbonic anhydrases in renal physiology. Kidney Int. 2007;71(2):103–15.
22. Wagner CA, Mohebbi N, Mira C, Brändli AW. The anion exchanger pendrin (SLC26A4) and renal acid-base homeostasis. Cell Physiol Biochem. 2011;28(3):497–504.
23. Palmer BF, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021;38:949–68.
24. Alexander RT, Kurman JS, Jacinto J. Renal tubular acidosis. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Springer; 2016. p. 973–91.
25. Chang MY, Lu KC, Lin SH. Role of pendrin in acid-base balance. Electrolyte Blood Press. 2009;7(1):20–4.
26. Wall SM, Pech V, Mount DB. The role of pendrin in renal physiology. Annu Rev Physiol. 2015;77:363–78.
27. Kapoor A, Chopra A. Role of Ayurveda in the management of chronic kidney disease: a case study. J Ayurveda Case Rep. 2020;3(1):14–9.
28. Batlle D, Haque SK. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol Dial Transplant. 2012;27(10):3691–704.
29. Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. Am J Kidney Dis. 2016;68(3):488–98.
30. Pereira PC, Miranda DM, Oliveira EA. Molecular pathophysiology of renal tubular acidosis. Curr Genomics. 2009;10(1):51–9.
31. Binu S. Chandanasava: Benefits, ingredients, methods, dosage and side effects [Internet]. 2021 Aug 24 [cited 2025 May 14]. Available from: https://www.ayurtimes.com/chandanasava/
32. Vinothkanna A, Krishnan V, Pugazhendhi A, Arulvasu C, Karunakaran K, Kumar SS, et al. GC-MS and Network Pharmacology Analysis of the Ayurvedic Fermented Medicine, Chandanasava, Against Chronic Kidney and Cardiovascular Diseases. Appl Biochem Biotechnol. 2023;195(5):2803–28.
33. Cheng C, Xu D, Liu X, Lin Y, Li W. The Effects of Oral Sodium Bicarbonate on Renal Function and Cardiovascular Risk in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ther Clin Risk Manag. 2021;17:1321–33.
| Volume | 03 |
| Issue | 02 |
| Received | 27/12/2024 |
| Accepted | 14/05/2025 |
| Published | 09/07/2025 |
| Publication Time | 194 Days |
PlumX Metrics